HIGHLIGHTS
- who: Rahat A. Memon et al. from the Internal Medicine, Abington Memorial Hospital, Abington, USA Medical School, Islamic Azad University, Tehran have published the research: Review began 07/19/2022 Review ended 07/23/2022 Published 07/26/2022 © Copyright, in the Journal: (JOURNAL) of July/26,/2022
- what: The current meta-analysis was conducted to compare the efficacy of dapagliflozin and empagliflozin in preventing cardiovascular events in patients with type 2 diabetes.
- future: In the future more prospective studies need to be carried out to identify which of these two drugs are . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.